Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 2/20 | 0.56 |
| ▸ | IGF1R | P08069 | 3/20 | 0.54 |
| ▸ | ULK1 | O75385 | 2/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12892936 | 0.93 | ZAP70 (0.54) | ZAP70IGF1RULK1PTK2EGFR | |
| SCHEMBL12780183 | 0.91 | IGF1R (0.54) | ZAP70IGF1RULK1PTK2EGFR | |
| SCHEMBL12780613 | 0.89 | MAPK9 (0.58) | IGF1RULK1PTK2EGFRMAPK1 | |
| SCHEMBL12780187 | 0.85 | ULK1 (0.58) | IGF1RULK1PTK2EGFRMAPK1 | |
| SCHEMBL12781575 | 0.84 | ZAP70 (0.56) | ZAP70IGF1RULK1PTK2EGFR | |
| SCHEMBL17547457 | 0.81 | ULK1 (0.64) | ZAP70IGF1RULK1PTK2EGFR | |
| SCHEMBL12781588 | 0.80 | ALK (0.57) | IGF1RULK1PTK2EGFRMAPK1 | |
| SCHEMBL1707698 | 0.79 | PTK2 (0.64) | ZAP70IGF1RULK1PTK2EGFR | |
| SCHEMBL12780619 | 0.78 | ZAP70 (0.69) | ZAP70IGF1RULK1PTK2EGFR | |
| SCHEMBL12780617 | 0.77 | ZAP70 (0.68) | ZAP70IGF1RULK1PTK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | ZAP70 341/4885IGF1R 4627/4885ULK1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.